Company intelligence / Profile preview

Think Bioscience

Boulder, Colorado, United Statesthinkbioscience.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Think Bioscience has demonstrated proof-of-concept by discovering a novel allosteric inhibitor of PTP1B using its synthetic biology platform. The company reports strong preclinical data for its lead programs but has not yet advanced candidates into clinical trials. Its approach enables identification of new functional pockets on difficult-to-drug protein targets, with early validation in multiple target classes including PTPs and kinases.[3][4]

Therapeutic areas: CardiovascularEndocrinologyImmunologyOncologyNeurology
Modalities: small molecules
Industry: Biotech

Partnerships

University of Colorado Boulder (contract research/support)[3]New York University (molecule optimization support)[3]

Beyond the preview

Go deeper on Think Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Think Bioscience.

Explore the full profile